Sintilimab

Generic Name
Sintilimab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2072873-06-2
Unique Ingredient Identifier
8FU7FQ8UPK
Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma

Phase 2
Recruiting
Conditions
Esophagogastric Junction Adenocarcinoma
Interventions
Drug: Sintilimab
First Posted Date
2021-12-28
Last Posted Date
2024-01-16
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
37
Registration Number
NCT05170503
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Phase 2
Not yet recruiting
Conditions
Hepatocellular Carcinoma
Interventions
Drug: Donafenib
Drug: Sintilimab
Other: HAIC
First Posted Date
2021-12-22
Last Posted Date
2021-12-22
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
30
Registration Number
NCT05166772

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC

First Posted Date
2021-12-21
Last Posted Date
2021-12-21
Lead Sponsor
Peking University
Target Recruit Count
40
Registration Number
NCT05165407
Locations
🇨🇳

Bejing cancer hospital, Beijing, Beijing, China

🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer

First Posted Date
2021-12-17
Last Posted Date
2021-12-17
Lead Sponsor
Fudan University
Target Recruit Count
152
Registration Number
NCT05161572
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)

First Posted Date
2021-11-29
Last Posted Date
2021-11-29
Lead Sponsor
Jun-Lin Yi, MD
Target Recruit Count
50
Registration Number
NCT05136768
Locations
🇨🇳

Cancer hospital, Chinese Academy of Medical Sciences, Beijing, China

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

First Posted Date
2021-11-11
Last Posted Date
2023-02-23
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
30
Registration Number
NCT05118334
Locations
🇨🇳

The First Hospital of Jilin University, Changchun, Jilin, China

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

First Posted Date
2021-11-11
Last Posted Date
2024-03-26
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
500
Registration Number
NCT05116462
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

First Posted Date
2021-11-09
Last Posted Date
2021-11-24
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
23
Registration Number
NCT05113355
Locations
🇨🇳

The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

🇨🇳

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer

First Posted Date
2021-11-03
Last Posted Date
2021-12-28
Lead Sponsor
The Affiliated Hospital of Xuzhou Medical University
Target Recruit Count
20
Registration Number
NCT05105672
Locations
🇨🇳

The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

Cryoablation Combined With Sintilimab Plus Lenvatinib In Previously Treated Unresectable Liver Metastasis From Solid Tumors

First Posted Date
2021-10-28
Last Posted Date
2022-11-10
Lead Sponsor
Fudan University
Target Recruit Count
25
Registration Number
NCT05098847
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy